ADVFN Logo
Registration Strip Icon for default Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.

VNRX VolitionRX Limited

0.743
0.00 (0.00%)
Pre Market
Last Updated: 04:00:00
Delayed by 15 minutes

Period:

Draw Mode:

Volume 0
Bid Price
Ask Price
News -
Day High

Low
0.55

52 Week Range

High
2.10

Day Low
Company Name Stock Ticker Symbol Market Type
VolitionRX Limited VNRX AMEX Common Stock
  Price Change Change Percent Stock Price Last Traded
0.00 0.00% 0.743 04:00:00
Open Price Low Price High Price Close Price Prev Close
0.743
Trades Volume Avg Volume 52 Week Range
0 0 - 0.55 - 2.10
Last Trade Time Type Quantity Stock Price Currency
- 0 $ 0.743 USD

VolitionRX Limited Financials

Market Cap Shares in Issue Float Revenue Profit/Loss EPS PE Ratio
58.23M 78.69M - 306k -30.27M -0.38 -
Short Interest Dividends Per Share Dividend Yield Ex-Div Date Insider B/S Insider % Owned
- - - -

more financials information »

VolitionRX News

Loading Messages....

{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}}

Loading Messages....


No posts yet, be the first! No VNRX Message Board. Create One! See More Posts on VNRX Message Board See More Message Board Posts

Historical VNRX Price Data

Period Open High Low VWAP Avg. Daily Vol Change %
1 Week0.82840.8420.700.7401371313,539-0.0854-10.31%
1 Month1.011.100.700.8219301141,454-0.267-26.44%
3 Months1.091.230.700.9365573127,787-0.347-31.83%
6 Months0.70361.230.550.8514518187,5190.03945.60%
1 Year1.702.100.551.08166,506-0.957-56.29%
3 Years3.514.14010.552.09140,802-2.77-78.83%
5 Years3.117.690.553.15184,925-2.37-76.11%

VolitionRX Description

VolitionRX Ltd is a us-based multi-national life sciences company. It is engaged in developing easy to use blood-based tests to accurately diagnose a range of cancers. The development pipeline includes assays to be used for symptomatic patients or asymptomatic populations. The company has developed more than 30 blood-based assays to detect specific biomarkers. It also develops Nucleosomics tests for several major cancers including CRC, pancreatic, lung and aggressive prostate. In addition, the company engages in the process of developing HyperGenomics tissue and blood-based tests to determine disease subtype following initial diagnosis and to help decide the appropriate therapy.

Your Recent History

Delayed Upgrade Clock